Clinical implications of tumour-based BRC

Tracy Stockley, PhD, FCCMG, FACMGAssociate Director, Genome Diagnostics, Department of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto ON
Raymond Kim, MD, PhD, FRCPC, FCCMG, FACMGMedical Geneticist, Assistant Professor, Department of Medicine, University of Toronto, Toronto ON

Session 1:
Tumour-based BRCA1/2 mutation testing: The UHN genome diagnostics experience
At the end of this session participants will be able to:
• Provide an overview of germline versus tumour-based (germline and somatic) BRCA1/2 mutation testing; differences and caveats for somatic testing
• Relay the benefits of BRCA1/2 mutation tumour-based testing
• Outline UHN’s experience of implementing BRCA1/2 tumour testing, including discussion 3. of sample preparation, testing methodologies and somatic variant interpretation
Session 2:
Clinical integration of somatic and germline BRCA1/2 mutation testing: In future, how do they co-exist?
At the end of this session participants will be able to:
• Understand how the molecular basis of ovarian cancer, both germline and somatic mutations, may inform clinical treatment decisions
• Discuss potential clinical implementation models of somatic BRCA1/2 mutation testing, including test ordering and post-test counselling needs
• Relay challenges and opportunities to integrating tumour-based testing into current germline testing workflows
• Understand the role of the multidisciplinary team in enabling tumour-based BRCA1/2 mutation testing

Question Title

* 1. Please rate the Session by circling the appropriate number:
Rating Scale:1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly Agree

  1 2 3 4 5
Sufficient time was allowed for audience participation/active learning
The facilities were satisfactory.
The session was free from commercial bias
Overall, I would rate this Symposium as excellent

Question Title

* 2. Please asses the Speakers by circling the appropriate number.
Rating Scale: 1 Poor, 2 Fair, 3 Good, 4 Very Good, 5 Outstanding
Tracy Stockley, PhD, FCCMG, FACMGAssociate Director, Genome Diagnostics, Department of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto ON

  1 2 3 4 5
Clarity of
Met Stated Objectives
Balanced & Unbiased
Relevant to Practice Overall
Time for Active Learning

Question Title

* 3. Please asses the Speakers by circling the appropriate number.
Rating Scale: 1 Poor, 2 Fair, 3 Good, 4 Very Good, 5 Outstanding
Raymond Kim, MD, PhD, FRCPC, FCCMG, FACMGMedical Geneticist, Assistant Professor, Department of Medicine, University of Toronto, Toronto ON

  1 2 3 4 5
Clarity of
Met Stated Objectives
Balanced & Unbiased
Relevant to Practice Overall
Time for Active Learning

Question Title

* 4. As a result of attending this session, I am planning to: (please check one)

  YES NO
a) Discuss the session with my colleagues
b) Pursue additional learning activities.
c) Complete a Personal Learning Project.
d) Not change my practice.
e) Change my practice.

Question Title

* 5. Please explain the change you are planning to make or the learning you plan to complete:

Question Title

* 6. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 7. General comments about individual speakers

Question Title

* 8. What topics need to be addressed at future conferences to keep you up to date in your profession?

T